Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

180.27B

Market cap180.27B

Price-Earnings ratio

21.53

Price-Earnings ratio21.53

Dividend yield

2.16%

Dividend yield2.16%

Average volume

6.78M

Average volume6.78M

High today

$146.95

High today$146.95

Low today

$143.70

Low today$143.70

Open price

$145.02

Open price$145.02

Volume

6.92M

Volume6.92M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$93.37

52 Week low$93.37

Stock Snapshot

As of today, Gilead Sciences(GILD) shares are valued at $143.70. The company's market cap stands at 180.27B, with a P/E ratio of 21.53 and a dividend yield of 2.2%.

On 2026-03-12, Gilead Sciences(GILD) stock traded between a low of $143.70 and a high of $146.95. Shares are currently priced at $143.70, which is 0.0% above the low and -2.2% below the high.

The Gilead Sciences(GILD)'s current trading volume is 6.92M, compared to an average daily volume of 6.78M.

In the last year, Gilead Sciences(GILD) shares hit a 52-week high of $157.29 and a 52-week low of $93.37.

GILD News

Simply Wall St 9h

Assessing Gilead Sciences Valuation After Recent Share Price Momentum And Mixed Fair Value Signals

Advertisement Why Gilead Sciences (GILD) is on investors’ radar today Gilead Sciences (GILD) has drawn fresh attention after recent share price moves, includi...

Simply Wall St 1d

Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification

Gilead Sciences (NasdaqGS:GILD) plans to acquire Arcellx in a deal valued at up to $7.8b. The transaction is aimed at expanding Gilead's cancer cell therapy pi...

Simply Wall St 3d

Is New HIV Switch Data Reframing the Investment Case for Gilead Sciences’ Lenacapavir Platform?

In February 2026, Gilead Sciences presented Phase 3 ARTISTRY-1 and ARTISTRY-2 data showing its investigational single-tablet bictegravir/lenacapavir HIV regimen...

Analyst ratings

73%

of 33 ratings

Buy

72.7%

Hold

21.2%

Sell

6.1%

More GILD News

Nasdaq 3d

Gilead Sciences Outperforms Broader Market: What You Need to Know

Gilead Sciences (GILD) closed the most recent trading day at $146.63, moving +1.88% from the previous trading session. This move outpaced the S&P 500's daily ga...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.